Wegovy demonstrates significant and sustained weight loss

Results from the STEP 5 Phase IIIb trial, presented today at the ObesityWeek 2021 interactive congress, showed that adults treated with Wegovy (semaglutide 2.4mg injection) achieved significant and sustained weight loss over the two-year study period, Danish diabetes care giant Novo Nordisk (NOV: N) announced.

The STEP 5 trial investigated Wegovy versus placebo, both used with a reduced calorie meal plan and increased physical activity for the treatment of obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/ m2) in 304 adults with at least one weight-related comorbidity for 104 weeks (two years).1

In the STEP 5 trial, results showed that Wegovy used with a reduced calorie meal plan and increased physical activity significantly reduced body weight from baseline to week 104 compared to placebo (-15.2% vs -2.6%, estimated treatment difference: -12.6% -points [95% CI: -15.3, -9.8]; p<0.0001). The study also demonstrated that adults with overweight or obesity were more likely to lose at least 5% of their body weight with Wegovy vs placebo (77.1% vs 34.4%; p<0.0001).